Immune Tolerance; Sigma Receptor as a Therapeutic Target
免疫耐受;
基本信息
- 批准号:6352379
- 负责人:
- 金额:$ 21.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-01 至 2004-08-31
- 项目状态:已结题
- 来源:
- 关键词:T lymphocyte cellular immunity clone cells drug receptors embryo /fetus death genetically modified animals human subject immune tolerance /unresponsiveness immunosuppression laboratory mouse ligands placenta pregnancy immunology progesterone protein protein interaction receptor binding receptor expression yeast two hybrid system
项目摘要
DESCRIPTION (provided by applicant): The goal of this project is to gather
evidence in support of a novel strategy for the induction of immune tolerance,
namely to use sigma 1 receptor as a potential therapeutic target. Sigma 1
receptor is defined as a specific binding site for various psychoactive drugs
such as haloperidol and pentazocine. This receptor has been recently cloned
and characterized. It is a membrane-bound protein found primarily in
intracellular sites. It is expressed in various tissues including immune cells
and placenta. There is compelling evidence for an immunosuppressive role of
sigma 1 receptor-specific ligands. The role of this receptor in immune
function has received increasing attention in recent years as it has become
apparent that progesterone is a putative endogenous ligand for this receptor.
The goal of this project is to delineate the molecular events involved in the
immunosuppressive function of sigma 1 receptor and to investigate the possible
role of progesterone in the maintenance of maternal tolerance toward placental
allograft. This project will test the following hypotheses: 1) Progesterone
and several pharmacological ligands suppress the function and proliferation of
T lymphocytes by acting as specific ligands for the sigma 1 receptor; 2) sigma
1 receptor produces its effects by influencing the function of other cellular
proteins in T lymphocytes and placenta via protein-protein interaction; 3)
Abolition of sigma 1 receptor gene expression by targeted disruption of the
gene in a mouse model will lead to maternal intolerance of the placental
allograft. Three specific aims are proposed to test these hypotheses. Specific
Aim 1 is to study the expression of sigma 1 receptor in quiescent and activated T lymphocytes and to establish the role of this receptor in the
suppression of T cell function. This will be done by analyzing the expression
of sigma 1 receptor at the molecular and functional level in T lymphocytes
before and after activation. The obligatory role of sigma 1 receptor in T cell
function will be evaluated by analyzing the biological effects of sigma 1
receptor-specific ligands in sigma 1 receptor-positive (control) and sigma 1
receptor-negative (stable transfectants expressing antisense sigma 1 receptor
mRNA) Jurkat cells. Specific Aim 2 is to identify the proteins in human
placenta and in T lymphocytes that interact with sigma 1 receptor using the
yeast two-hybrid system. Identification of the target proteins that interact
with sigma 1 receptor will help to unravel the molecular mechanisms of cell
signaling mediated by sigma 1 receptor. Specific Aim 3 is to determine, using
sigma 1 receptor knockout mice, whether the absence of the receptor manifests
itself as embryo lethality, an inability of the embryo to defend itself
against maternal immune system, or as an inability of the maternal immune
system to maintain tolerance toward the placental allograft. This project may
have significant physiological, clinical, and therapeutic relevance. The
proposed studies may lead to a better understanding of the induction of
maternal tolerance toward placental allograft and may provide the basis for
future efforts to examine the therapeutic potential of sigma 1
receptor-specific ligands as effective immunosuppressants.
描述(申请者提供):该项目的目标是收集
支持诱导免疫耐受的新策略的证据,
即利用Sigma 1受体作为潜在的治疗靶点。西格玛1
受体被定义为各种精神活性药物的特定结合部位
如氟哌啶醇和五唑西林。这种受体最近被克隆了。
并以此为特征。它是一种膜结合蛋白,主要存在于
细胞内的位置。它在包括免疫细胞在内的各种组织中表达。
还有胎盘。有令人信服的证据表明它具有免疫抑制作用。
Sigma 1受体特异性配体。该受体在免疫中的作用
函数近年来受到越来越多的关注,因为它已经成为
显然,孕酮是该受体的内源性配体。
这个项目的目标是勾勒出
Sigma-1受体的免疫抑制功能及其可能的研究
孕酮在维持母体对胎盘耐受性中的作用
异体移植。这个项目将检验以下假设:1)黄体酮
几种药物配体抑制血管内皮细胞的功能和增殖
T淋巴细胞作为Sigma-1受体的特异性配体;2)Sigma
1受体通过影响其他细胞的功能发挥作用。
蛋白质-蛋白质相互作用在T淋巴细胞和胎盘中的蛋白质;
靶向干扰Sigma-1受体基因表达
小鼠模型中的基因会导致母体对胎盘的不耐受
异体移植。为了检验这些假说,本文提出了三个具体目标。特定的
目的1研究Sigma-1受体在静止期和活化T淋巴细胞中的表达,并探讨该受体在慢性粒细胞白血病发病中的作用。
抑制T细胞功能。这将通过分析表达式来完成
T淋巴细胞中Sigma-1受体在分子和功能水平的表达
激活前和激活后。Sigma-1受体在T细胞中的必备作用
将通过分析Sigma 1的生物学效应来评估其功能
Sigma-1受体阳性(对照)和Sigma-1中的受体特异性配体
受体阴性(稳定表达反义Sigma 1受体的转染体
M RNA)Jurkat细胞。具体目标2是鉴定人类体内的蛋白质
胎盘和与Sigma-1受体相互作用的T淋巴细胞中
酵母双杂交系统。相互作用的靶蛋白的鉴定
通过Sigma 1受体将有助于解开细胞的分子机制
Sigma 1受体介导的信号转导。具体目标3是确定,使用
Sigma 1受体基因敲除小鼠,是否表现为受体缺失
胚胎本身是致命的,胚胎没有能力保护自己
对抗母体免疫系统,或作为母体免疫系统的无能为力
维持对同种异体胎盘移植耐受性的系统。这个项目可能
具有显著的生理、临床和治疗相关性。这个
拟议的研究可能会导致更好地理解诱导
母体对同种异体胎盘移植的耐受性,可能为
研究Sigma-1治疗潜力的未来努力
受体特异性配体作为有效的免疫抑制剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VADIVEL GANAPATHY其他文献
VADIVEL GANAPATHY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VADIVEL GANAPATHY', 18)}}的其他基金
Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches
氨基酸转运蛋白 SLC38A5 作为 TNBC 的药物靶点:用遗传和药理学方法进行评估
- 批准号:
10576760 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
SLC5A8 is a conditional tumor suppressor in colon linked to dietary fiber content
SLC5A8 是结肠中的一种条件性肿瘤抑制因子,与膳食纤维含量有关
- 批准号:
9751215 - 财政年份:2015
- 资助金额:
$ 21.53万 - 项目类别:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
“饿死肿瘤细胞”:SLC6A14作为结肠癌的药物靶点
- 批准号:
8077946 - 财政年份:2010
- 资助金额:
$ 21.53万 - 项目类别:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
“饿死肿瘤细胞”:SLC6A14作为结肠癌的药物靶点
- 批准号:
7963106 - 财政年份:2010
- 资助金额:
$ 21.53万 - 项目类别:
Molecular Analysis of a Novel Opioid Peptide Transporter
新型阿片肽转运蛋白的分子分析
- 批准号:
7230316 - 财政年份:2006
- 资助金额:
$ 21.53万 - 项目类别:
Molecular Analysis of a Novel Opioid Peptide Transporter
新型阿片肽转运蛋白的分子分析
- 批准号:
7127794 - 财政年份:2006
- 资助金额:
$ 21.53万 - 项目类别:
相似海外基金
Immunoregulation of cellular immunity and tissue homeostasis during Chagas' disease
恰加斯病期间细胞免疫和组织稳态的免疫调节
- 批准号:
10448950 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
Gingival vaccination strategy to induce both humoral and cellular immunity ideal for elderly vaccination
诱导体液和细胞免疫的牙龈疫苗接种策略非常适合老年人疫苗接种
- 批准号:
22K09932 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
mRNA encoding of immune receptor-targeting antibodies for the augmentation of vaccine-elicited cellular immunity.
编码免疫受体靶向抗体的 mRNA,用于增强疫苗引发的细胞免疫。
- 批准号:
10508093 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
From mtDNA stress to cellular immunity: Triggers, Mechanisms and Effectors
从线粒体DNA应激到细胞免疫:触发因素、机制和效应器
- 批准号:
10501418 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
From mtDNA stress to cellular immunity: Triggers, Mechanisms and Effectors
从线粒体DNA应激到细胞免疫:触发因素、机制和效应器
- 批准号:
10650823 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
Longitudinal SARS-CoV-2 mRNA vaccine-induced mucosal, serological, and cellular immunity in children and human milk
纵向 SARS-CoV-2 mRNA 疫苗诱导儿童和母乳中的粘膜、血清学和细胞免疫
- 批准号:
10568736 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
SHINING A LIGHT ON BAT CELLULAR IMMUNITY FOLLOWING VIRUS INFECTION
揭示病毒感染后蝙蝠细胞免疫
- 批准号:
10449406 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
From mtDNA stress to cellular immunity: Triggers, Mechanisms and Effectors
从线粒体DNA应激到细胞免疫:触发因素、机制和效应器
- 批准号:
10797812 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
Longitudinal SARS-CoV-2 mRNA vaccine-induced mucosal, serological, and cellular immunity in children and human milk
纵向 SARS-CoV-2 mRNA 疫苗诱导儿童和母乳中的粘膜、血清学和细胞免疫
- 批准号:
10895221 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:
mRNA encoding of immune receptor-targeting antibodies for the augmentation of vaccine-elicited cellular immunity.
编码免疫受体靶向抗体的 mRNA,用于增强疫苗引发的细胞免疫。
- 批准号:
10662571 - 财政年份:2022
- 资助金额:
$ 21.53万 - 项目类别:














{{item.name}}会员




